OR WAIT null SECS
December 23, 2021
Reporting of PRO in oncology clinical trials increased after standards from ISOQOL and others were published in 2013.
December 17, 2021
Because of a COVID-19 related shortage, facilities may not have immediate access to Actemra, which is required as part of the REMS programs for CAR T-cell therapies.
December 14, 2021
Blood cancer patients who had at least some antibodies after the first two doses are likely to produce large amounts after the third vaccination.
December 06, 2021
Both Copiktra and Farydak had received accelerated approvals, and the FDA had required confirmatory trials. Secura Bio has determined such trials are not feasible.
December 04, 2021
The approval marks the ninth indication for Darzalex Faspro, the only subcutaneous anti-CD38 monoclonal antibody approved to treat multiple myeloma across multiple treatment regimens.
December 03, 2021
The warnings section of Inrebic, a JAK inhibitor to treat a bone marrow cancer, now includes information about the cardiovascular risk associated with Xeljanz, another JAK inhibitor to treat arthritis.
November 30, 2021
The regulatory agency has set a Prescription Drug User Fee Act date during the first quarter of 2022
Cytalux is the first imagining agent to illuminate ovarian cancer during surgery.
November 18, 2021
Keytruda is the first immunotherapy approved for treatment of patients with early renal cell carcinoma after surgery.
Most of the patients with no immune response after the two-dose regimen responded well to a third shot.
